MTOR signaling in disease

Current Opinion in Cell Biology

Volumn 23, Issue 6, 2011, Pages 744-755

  Dazert, Eva ^a   Hall, Michael N ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; GEFITINIB; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RAF PROTEIN; RAPAMYCIN; RAS PROTEIN; TAMOXIFEN; TEMSIROLIMUS; TRASTUZUMAB;

ACUTE GRANULOCYTIC LEUKEMIA; BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INVASION; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DIABETES MELLITUS; DRUG EFFICACY; FATTY LIVER; GLIOBLASTOMA; HUMAN; INFLAMMATION; INNATE IMMUNITY; INSULIN RESISTANCE; KIDNEY CANCER; KIDNEY CARCINOMA; LEUKEMIA; LIFESPAN; LONGEVITY; LUNG CANCER; MELANOMA; METABOLIC DISORDER; METASTASIS; NEOPLASM; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; THYROID CANCER; TUMOR GROWTH;

ANIMALS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; HUMANS; MAMMALS; NEOPLASMS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

MAMMALIA;

EID: 82555166000     PISSN: 09550674     EISSN: 18790410     Source Type: Journal    
DOI: 10.1016/j.ceb.2011.09.003     Document Type: Review

References (168)

1. Loewith R., Jacinto E., Wullschleger S., Lorberg A., Crespo J.L., Bonenfant D., Oppliger W., Jenoe P., Hall M.N. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Molecular Cell 2002, 10:457-468.
2. Wullschleger S., Loewith R., Hall M.N. TOR signaling in growth and metabolism. Cell 2006, 124:471-484.
3. Zoncu R., Efeyan A., Sabatini D.M. mTOR: from growth signal integration to cancer, diabetes and ageing. Nature Reviews. Molecular Cell Biology 2011, 12:21-35.
4. Jacinto E., Loewith R., Schmidt A., Lin S., Ruegg M.A., Hall A., Hall M.N. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nature Cell Biology 2004, 6:1122-1128.
5. Sarbassov D.D., Ali S.M., Sengupta S., Sheen J.H., Hsu P.P., Bagley A.F., Markhard A.L., Sabatini D.M. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Molecular Cell 2006, 22:159-168.
6. Zinzalla V., Stracka D., Oppliger W., Hall M.N. Activation of mTORC2 by association with the ribosome. Cell 2011, 144:757-768.
7. Oh W.J., Wu C.C., Kim S.J., Facchinetti V., Julien L.A., Finlan M., Roux P.P., Su B., Jacinto E. mTORC2 can associate with ribosomes to promote cotranslational phosphorylation and stability of nascent Akt polypeptide. The EMBO Journal 2010, 29:3939-3951.
8. Inoki K., Ouyang H., Zhu T., Lindvall C., Wang Y., Zhang X., Yang Q., Bennett C., Harada Y., Stankunas K., et al. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 2006, 126:955-968.
9. Kaeberlein M., Powers R.W., Steffen K.K., Westman E.A., Hu D., Dang N., Kerr E.O., Kirkland K.T., Fields S., Kennedy B.K. Regulation of yeast replicative life span by TOR and Sch9 in response to nutrients. Science 2005, 310:1193-1196.
10. Kapahi P., Zid B.M., Harper T., Koslover D., Sapin V., Benzer S. Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway. Current Biology: CB 2004, 14:885-890.
11. Vellai T., Takacs-Vellai K., Zhang Y., Kovacs A.L., Orosz L., Muller F. Genetics: influence of TOR kinase on lifespan in C. elegans. Nature 2003, 426:620.
12. Harrison D.E., Strong R., Sharp Z.D., Nelson J.F., Astle C.M., Flurkey K., Nadon N.L., Wilkinson J.E., Frenkel K., Carter C.S., et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009, 460:392-395.
13. Blagosklonny M.V., Hall M.N. Growth and aging: a common molecular mechanism. Aging 2009, 1:357-362.
14. Blagosklonny M.V. Calorie restriction: decelerating mTOR-driven aging from cells to organisms (including humans). Cell Cycle 2010, 9:683-688.
15. Kapahi P., Chen D., Rogers A.N., Katewa S.D., Li P.W., Thomas E.L., Kockel L. With TOR, less is more: a key role for the conserved nutrient-sensing TOR pathway in aging. Cell Metabolism 2010, 11:453-465.
16. Zid B.M., Rogers A.N., Katewa S.D., Vargas M.A., Kolipinski M.C., Lu T.A., Benzer S., Kapahi P. 4E-BP extends lifespan upon dietary restriction by enhancing mitochondrial activity in Drosophila. Cell 2009, 139:149-160.
17. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
18. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
19. Roberts P.J., Der C.J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007, 26:3291-3310.
20. Shaw R.J., Cantley L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006, 441:424-430.
21. Davis B.N., Hata A. microRNA in Cancer-the involvement of aberrant microRNA biogenesis regulatory pathways. Genes & Cancer 2010, 1:1100-1114.
22. Oneyama C., Ikeda J., Okuzaki D., Suzuki K., Kanou T., Shintani Y., Morii E., Okumura M., Aozasa K., Okada M. MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways. Oncogene 2011, 30:3489-3501.
23. Porstmann T., Santos C.R., Griffiths B., Cully M., Wu M., Leevers S., Griffiths J.R., Chung Y.L., Schulze A. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metabolism 2008, 8:224-236.
24. Duvel K., Yecies J.L., Menon S., Raman P., Lipovsky A.I., Souza A.L., Triantafellow E., Ma Q., Gorski R., Cleaver S., et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Molecular Cell 2010, 39:171-183.
25. Schieke S.M., Phillips D., McCoy J.P., Aponte A.M., Shen R.F., Balaban R.S., Finkel T. The mammalian target of rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity. The Journal of Biological Chemistry 2006, 281:27643-27652.
26. Colombi M., Molle K.D., Benjamin D., Rattenbacher-Kiser K., Schaefer C., Betz C., Thiemeyer A., Regenass U., Hall M.N., Moroni C. Genome-wide shRNA screen reveals increased mitochondrial dependence upon mTORC2 addiction. Oncogene 2011, 30:1551-1565.
27. Neufeld T.P. TOR-dependent control of autophagy: biting the hand that feeds. Current Opinion in Cell Biology 2010, 22:157-168.
28. Ganley I.G., Lam du H., Wang J., Ding X., Chen S., Jiang X. ULK1.ATG13.FIP200 complex mediates mTOR signaling and is essential for autophagy. The Journal of Biological Chemistry 2009, 284:12297-12305.
29. Yecies J.L., Manning B.D. mTOR links oncogenic signaling to tumor cell metabolism. Journal of Molecular Medicine 2011, 89:221-228.
30. Yecies J.L., Manning B.D. Transcriptional control of cellular metabolism by mTOR signaling. Cancer Research 2011, 71:2815-2820.
31. Ho V.W., Leung K., Hsu A., Luk B., Lai J., Shen S.Y., Minchinton A.I., Waterhouse D., Bally M.B., Lin W., et al. A low carbohydrate, high protein diet slows tumor growth and prevents cancer initiation. Cancer Research 2011, 71:4484-4493.
32. Sauter G., Maeda T., Waldman F.M., Davis R.L., Feuerstein B.G. Patterns of epidermal growth factor receptor amplification in malignant gliomas. The American Journal of Pathology 1996, 148:1047-1053.
33. Benito R., Gil-Benso R., Quilis V., Perez M., Gregori-Romero M., Roldan P., Gonzalez-Darder J., Cerda-Nicolas M., Lopez-Gines C. Primary glioblastomas with and without EGFR amplification: relationship to genetic alterations and clinicopathological features. Neuropathology: Official Journal of the Japanese Society of Neuropathology 2010, 30:392-400.
34. Arteaga C.L. EGF receptor mutations in lung cancer: from humans to mice and maybe back to humans. Cancer Cell 2006, 9:421-423.
35. Moasser M.M. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 2007, 26:6469-6487.
36. Chua T.C., Merrett N.D. Clinicopathologic factors associated with HER2-Positive gastric cancer and its impact on survival outcomes - a systematic review. International Journal of Cancer 2011, doi:10.1002/ijc.26292.
37. Yuan T.L., Cantley L.C. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008, 27:5497-5510.
38. Steelman L.S., Chappell W.H., Abrams S.L., Kempf R.C., Long J., Laidler P., Mijatovic S., Maksimovic-Ivanic D., Stivala F., Mazzarino M.C., et al. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging 2011, 3:192-222.
39. Ligresti G., Militello L., Steelman L.S., Cavallaro A., Basile F., Nicoletti F., Stivala F., McCubrey J.A., Libra M. PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches. Cell Cycle 2009, 8:1352-1358.
40. Engelman J.A., Luo J., Cantley L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nature Reviews. Genetics 2006, 7:606-619.
41. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., Yan H., Gazdar A., Powell S.M., Riggins G.J., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304:554.
42. Lee J.W., Soung Y.H., Kim S.Y., Lee H.W., Park W.S., Nam S.W., Kim S.H., Lee J.Y., Yoo N.J., Lee S.H. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005, 24:1477-1480.
43. Campbell I.G., Russell S.E., Choong D.Y., Montgomery K.G., Ciavarella M.L., Hooi C.S., Cristiano B.E., Pearson R.B., Phillips W.A. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Research 2004, 64:7678-7681.
44. Oda K., Stokoe D., Taketani Y., McCormick F. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Research 2005, 65:10669-10673.
45. Qiu W., Schonleben F., Li X., Ho D.J., Close L.G., Manolidis S., Bennett B.P., Su G.H. PIK3CA mutations in head and neck squamous cell carcinoma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2006, 12:1441-1446.
46. Pedrero J.M., Carracedo D.G., Pinto C.M., Zapatero A.H., Rodrigo J.P., Nieto C.S., Gonzalez M.V. Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. International Journal of Cancer. Journal International du Cancer 2005, 114:242-248.
47. Simpson L., Parsons R. PTEN: life as a tumor suppressor. Experimental Cell Research 2001, 264:29-41.
48. Wang S.I., Puc J., Li J., Bruce J.N., Cairns P., Sidransky D., Parsons R. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Research 1997, 57:4183-4186.
49. Smith J.S., Tachibana I., Passe S.M., Huntley B.K., Borell T.J., Iturria N., O'Fallon J.R., Schaefer P.L., Scheithauer B.W., James C.D., et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. Journal of the National Cancer Institute 2001, 93:1246-1256.
50. Duerr E.M, Rollbrocker B., Hayashi Y., Peters N., Meyer-Puttlitz B., Louis D.N., Schramm J., Wiestler O.D., Parsons R., Eng C., et al. PTEN mutations in gliomas and glioneuronal tumors. Oncogene 1998, 16:2259-2264.
51. Rasheed B.K., Stenzel T.T., McLendon R.E., Parsons R., Friedman A.H., Friedman H.S., Bigner D.D., Bigner S.H. PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Research 1997, 57:4187-4190.
52. Mutter G.L., Lin M.C., Fitzgerald J.T., Kum J.B., Baak J.P., Lees J.A., Weng L.P., Eng C. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. Journal of the National Cancer Institute 2000, 92:924-930.
53. Tashiro H., Blazes M.S., Wu R., Cho K.R., Bose S., Wang S.I., Li J., Parsons R., Ellenson L.H. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Research 1997, 57:3935-3940.
54. Terakawa N., Kanamori Y., Yoshida S. Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. Endocrine-related Cancer 2003, 10:203-208.
55. Pollock P.M., Walker G.J., Glendening J.M., Que Noy T., Bloch N.C., Fountain J.W., Hayward N.K. PTEN inactivation is rare in melanoma tumours but occurs frequently in melanoma cell lines. Melanoma Research 2002, 12:565-575.
56. Birck A., Ahrenkiel V., Zeuthen J., Hou-Jensen K., Guldberg P. Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies. The Journal of Investigative Dermatology 2000, 114:277-280.
57. Reifenberger J., Wolter M., Bostrom J., Buschges R., Schulte K.W., Megahed M., Ruzicka T., Reifenberger G. Allelic losses on chromosome arm 10q and mutation of the PTEN (MMAC1) tumour suppressor gene in primary and metastatic malignant melanomas. Virchows Archiv: An International Journal of Pathology 2000, 436:487-493.
58. Ruggeri B.A., Huang L., Wood M., Cheng J.Q., Testa J.R. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Molecular Carcinogenesis 1998, 21:81-86.
59. Cheng J.Q., Godwin A.K., Bellacosa A., Taguchi T., Franke T.F., Hamilton T.C., Tsichlis P.N., Testa J.R. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:9267-9271.
60. Nakayama K., Nakayama N., Kurman R.J., Cope L., Pohl G., Samuels Y., Velculescu V.E., Wang T.L., Shih Ie M. Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biology & Therapy 2006, 5:779-785.
61. Bos J.L. ras oncogenes in human cancer: a review. Cancer Research 1989, 49:4682-4689.
62. Brink M., de Goeij A.F., Weijenberg M.P., Roemen G.M., Lentjes M.H., Pachen M.M., Smits K.M., de Bruine A.P., Goldbohm R.A., van den Brandt P.A. K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis 2003, 24:703-710.
63. Downward J. Targeting RAS signalling pathways in cancer therapy. Nature Reviews. Cancer 2003, 3:11-22.
64. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
65. Pollock P.M., Harper U.L., Hansen K.S., Yudt L.M., Stark M., Robbins C.M., Moses T.Y., Hostetter G., Wagner U., Kakareka J., et al. High frequency of BRAF mutations in nevi. Nature Genetics 2003, 33:19-20.
66. Xing M. BRAF mutation in thyroid cancer. Endocrine-related Cancer 2005, 12:245-262.
67. Garnett M.J., Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 2004, 6:313-319.
68. Sieben N.L., Macropoulos P., Roemen G.M., Kolkman-Uljee S.M., Jan Fleuren G., Houmadi R., Diss T., Warren B., Al Adnani M., De Goeij A.P., et al. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. The Journal of Pathology 2004, 202:336-340.
69. Sastry S.K., Elferink LA Checks and balances: interplay of RTKs and PTPs in cancer progression. Biochemical Pharmacology 2011, 82:435-440.
70. Sato T., Nakashima A., Guo L., Coffman K., Tamanoi F. Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer. Oncogene 2010, 29:2746-2752.
71. Menon S., Manning B.D. Common corruption of the mTOR signaling network in human tumors. Oncogene 2008, 27(Suppl. 2):S43-S51.
72. Memmott R.M., Dennis P.A. The role of the Akt/mTOR pathway in tobacco carcinogen-induced lung tumorigenesis. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2010, 16:4-10.
73. Balsara B.R., Pei J., Mitsuuchi Y., Page R., Klein-Szanto A., Wang H., Unger M., Testa J.R. Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 2004, 25:2053-2059.
74. Wislez M., Spencer M.L., Izzo J.G., Juroske D.M., Balhara K., Cody D.D., Price R.E., Hittelman W.N., Wistuba I.I., Kurie J.M. Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras. Cancer Research 2005, 65:3226-3235.
75. Han W., Gills J.J., Memmott R.M., Lam S., Dennis P.A. The chemopreventive agent myoinositol inhibits Akt and extracellular signal-regulated kinase in bronchial lesions from heavy smokers. Cancer Prevention Research 2009, 2:370-376.
76. Herrmann J.L., Byekova Y., Elmets C.A., Athar M. Liver kinase B1 (LKB1) in the pathogenesis of epithelial cancers. Cancer Letters 2011, 306:1-9.
77. Hollander M.C., Blumenthal G.M., Dennis P.A. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nature Reviews. Cancer 2011, 11:289-301.
78. Brown K.A., Hunger N.I., Docanto M., Simpson E.R. Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase. Breast Cancer Research and Treatment 2010, 123:591-596.
79. Ben Sahra I., Regazzetti C., Robert G., Laurent K., Le Marchand-Brustel Y., Auberger P., Tanti J.F., Giorgetti-Peraldi S., Bost F. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Research 2011, 71:4366-4372.
80. Whittaker S., Marais R., Zhu A.X. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010, 29:4989-5005.
81. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., de Oliveira A.C., Santoro A., Raoul J.L., Forner A., et al. Sorafenib in advanced hepatocellular carcinoma. The New England Journal of Medicine 2008, 359:378-390.
82. Wich C., Agaimy A., Strobel D., Wissniowski T.T., Hartmann A., Ocker M. Sustained treatment response of metastatic hepatocellular carcinoma with bevacizumab and sorafenib. World Journal of Gastroenterology: WJG 2010, 16:3592-3596.
83. Peck-Radosavljevic M. Hepatocellular carcinoma: the place of new medical therapies. Therapeutic Advances in Gastroenterology 2010, 3:259-267.
84. Alvarado Y., Mita M.M., Vemulapalli S., Mahalingam D., Mita A.C. Clinical activity of mammalian target of rapamycin inhibitors in solid tumors. Targeted Oncology 2011, 6:69-94.
85. Chapuis N., Tamburini J., Green A.S., Willems L., Bardet V., Park S., Lacombe C., Mayeux P., Bouscary D. Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, UK 2010, 24:1686-1699.
86. Kelly K.R., Rowe J.H., Padmanabhan S., Nawrocki S.T., Carew J.S. Mammalian target of rapamycin as a target in hematological malignancies. Targeted Oncology 2011, 6:53-61.
87. Ly C., Arechiga A.F., Melo J.V., Walsh C.M., Ong S.T. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. Cancer Research 2003, 63:5716-5722.
88. Kharas M.G., Deane J.A., Wong S., O'Bosky K.R., Rosenberg N., Witte O.N., Fruman D.A. Phosphoinositide 3-kinase signaling is essential for ABL oncogene-mediated transformation of B-lineage cells. Blood 2004, 103:4268-4275.
89. Care R.S., Valk P.J., Goodeve A.C., Abu-Duhier F.M., Geertsma-Kleinekoort W.M., Wilson G.A., Gari M.A., Peake I.R., Lowenberg B., Reilly J.T. Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. British Journal of Haematology 2003, 121:775-777.
90. Chen W., Drakos E., Grammatikakis I., Schlette E.J., Li J., Leventaki V., Staikou-Drakopoulou E., Patsouris E., Panayiotidis P., Medeiros L.J., et al. mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3-mutated acute myeloid leukemia cells. Molecular Cancer 2010, 9:292.
91. Xu Q., Simpson S.E., Scialla T.J., Bagg A., Carroll M. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 2003, 102:972-980.
92. Raffeld M., Jaffe E.S. bcl-1, t(11;14), and mantle cell-derived lymphomas. Blood 1991, 78:259-263.
93. Perez-Galan P., Dreyling M., Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 2011, 117:26-38.
94. De Benedetti A., Graff J.R. eIF-4E expression and its role in malignancies and metastases. Oncogene 2004, 23:3189-3199.
95. Hess G., Herbrecht R., Romaguera J., Verhoef G., Crump M., Gisselbrecht C., Laurell A., Offner F., Strahs A., Berkenblit A., et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2009, 27:3822-3829.
96. Curatolo P., Bombardieri R., Jozwiak S. Tuberous sclerosis. Lancet 2008, 372:657-668.
97. Mizuguchi M., Takashima S. Neuropathology of tuberous sclerosis. Brain & Development 2001, 23:508-515.
98. Yu J., Parkhitko A.A., Henske E.P. Mammalian target of rapamycin signaling and autophagy: roles in lymphangioleiomyomatosis therapy. Proceedings of the American Thoracic Society 2010, 7:48-53.
99. Piha-Paul S.A., Hong D.S., Kurzrock R. Response of lymphangioleiomyomatosis to a mammalian target of rapamycin inhibitor (temsirolimus)-based treatment. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2011, 29:e333-e335.
100. Bissler J.J., McCormack F.X., Young L.R., Elwing J.M., Chuck G., Leonard J.M., Schmithorst V.J., Laor T., Brody A.S., Bean J., et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. The New England Journal of Medicine 2008, 358:140-151.
101. Farooq A., Walker L.J., Bowling J., Audisio R.A. Cowden syndrome. Cancer Treatment Reviews 2010, 36:577-583.
102. Gwinn D.M., Shackelford D.B., Egan D.F., Mihaylova M.M., Mery A., Vasquez D.S., Turk B.E., Shaw R.J. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Molecular Cell 2008, 30:214-226.
103. Inoki K., Zhu T., Guan K.L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003, 115:577-590.
104. Choo A.Y., Yoon S.O., Kim S.G., Roux P.P., Blenis J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:17414-17419.
105. Thoreen C.C., Kang S.A., Chang J.W., Liu Q., Zhang J., Gao Y., Reichling L.J., Sim T., Sabatini D.M., Gray N.S. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. The Journal of Biological Chemistry 2009, 284:8023-8032.
106. Feldman M.E., Apsel B., Uotila A., Loewith R., Knight Z.A., Ruggero D., Shokat K.M. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biology 2009, 7:e38.
107. Maira S.M., Stauffer F., Brueggen J., Furet P., Schnell C., Fritsch C., Brachmann S., Chene P., De Pover A., Schoemaker K., et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Molecular Cancer Therapeutics 2008, 7:1851-1863.
108. Knight S.D., Adams N.D., Burgess J.L., Chaudhari A.M., Darcy M.G., Donatelli C.A., Luengo J.I., Newlander K.A., Parrish C.A., Ridgers L.H., et al. Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapamycin. ACS Medicinal Chemsitry Letters 2010, 1:39-43.
109. Apsel B., Blair J.A., Gonzalez B., Nazif T.M., Feldman M.E., Aizenstein B., Hoffman R., Williams R.L., Shokat K.M., Knight Z.A. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nature Chemical Biology 2008, 4:691-699.
110. Yu K., Toral-Barza L., Shi C., Zhang W.G., Lucas J., Shor B., Kim J., Verheijen J., Curran K., Malwitz D.J., et al. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Research 2009, 69:6232-6240.
111. Zhang Y.J., Duan Y., Zheng X.F. Targeting the mTOR kinase domain: the second generation of mTOR inhibitors. Drug Discovery Today 2011, 16:325-331.
112. Cornu MaM.N.H. mTORC1 and mTORC2 in energy homeostasis. The Enzymes: Structure, Function and Regulation of TOR Complexes from Yeasts to Mammals 2010, vol 28:263-278. Academic Press, Elsevier Inc.
113. Rachdi L., Balcazar N., Osorio-Duque F., Elghazi L., Weiss A., Gould A., Chang-Chen K.J., Gambello M.J., Bernal-Mizrachi E. Disruption of Tsc2 in pancreatic beta cells induces beta cell mass expansion and improved glucose tolerance in a TORC1-dependent manner. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:9250-9255.
114. Bentzinger C.F., Romanino K., Cloetta D., Lin S., Mascarenhas J.B., Oliveri F., Xia J., Casanova E., Costa C.F., Brink M., et al. Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy. Cell Metabolism 2008, 8:411-424.
115. Polak P., Cybulski N., Feige J.N., Auwerx J., Ruegg M.A., Hall M.N. Adipose-specific knockout of raptor results in lean mice with enhanced mitochondrial respiration. Cell Metabolism 2008, 8:399-410.
116. Mori H., Inoki K., Munzberg H., Opland D., Faouzi M., Villanueva E.C., Ikenoue T., Kwiatkowski D., MacDougald O.A., Myers M.G., et al. Critical role for hypothalamic mTOR activity in energy balance. Cell Metabolism 2009, 9:362-374.
117. Yecies J.L., Zhang H.H., Menon S., Liu S., Yecies D., Lipovsky A.I., Gorgun C., Kwiatkowski D.J., Hotamisligil G.S., Lee C.H., et al. Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways. Cell Metabolism 2011, 14:21-32.
118. Kenerson H.L., Yeh M.M., Yeung R.S. Tuberous sclerosis complex-1 deficiency attenuates diet-induced hepatic lipid accumulation. PLoS ONE 2011, 6:e18075.
119. Sengupta S., Peterson T.R., Laplante M., Oh S., Sabatini D.M. mTORC1 controls fasting-induced ketogenesis and its modulation by ageing. Nature 2010, 468:1100-1104.
120. Cybulski N., Polak P., Auwerx J., Ruegg M.A., Hall M.N. mTOR complex 2 in adipose tissue negatively controls whole-body growth. Proc Natl Acad Sci USA 2009, 106:9902-9907.
121. Kumar A., Lawrence J.C., Jung D.Y., Ko H.J., Keller S.R., Kim J.K., Magnuson M.A., Harris T.E. Fat cell-specific ablation of rictor in mice impairs insulin-regulated fat cell and whole-body glucose and lipid metabolism. Diabetes 2010, 59:1397-1406.
122. Le Bacquer O., Petroulakis E., Paglialunga S., Poulin F., Richard D., Cianflone K., Sonenberg N. Elevated sensitivity to diet-induced obesity and insulin resistance in mice lacking 4E-BP1 and 4E-BP2. The Journal of Clinical Investigation 2007, 117:387-396.
123. Catania C., Binder E., Cota D. mTORC1 signaling in energy balance and metabolic disease. International Journal of Obesity 2011, 35:751-761.
124. Um S.H., Frigerio F., Watanabe M., Picard F., Joaquin M., Sticker M., Fumagalli S., Allegrini P.R., Kozma S.C., Auwerx J., et al. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 2004, 431:200-205.
125. Li S., Brown M.S., Goldstein J.L. Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:3441-3446.
126. Postic C., Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. The Journal of Clinical Investigation 2008, 118:829-838.
127. Donnelly K.L., Smith C.I., Schwarzenberg S.J., Jessurun J., Boldt M.D., Parks E.J. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. The Journal of Clinical Investigation 2005, 115:1343-1351.
128. Newgard C.B., An J., Bain J.R., Muehlbauer M.J., Stevens R.D., Lien L.F., Haqq A.M., Shah S.H., Arlotto M., Slentz C.A., et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metabolism 2009, 9:311-326.
129. Khamzina L., Veilleux A., Bergeron S., Marette A. Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance. Endocrinology 2005, 146:1473-1481.
130. Godel M., Hartleben B., Herbach N., Liu S., Zschiedrich S., Lu S., Debreczeni-Mor A., Lindenmeyer M.T., Rastaldi M.P., Hartleben G., et al. Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. The Journal of Clinical Investigation 2011, 121:2197-2209.
131. Inoki K., Mori H., Wang J., Suzuki T., Hong S., Yoshida S., Blattner S.M., Ikenoue T., Ruegg M.A., Hall M.N., et al. mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. The Journal of Clinical Investigation 2011, 121:2181-2196.
132. Jalving M., Gietema J.A., Lefrandt J.D., de Jong S., Reyners A.K., Gans R.O., de Vries E.G. Metformin: taking away the candy for cancer?. European Journal of Cancer 2010, 46:2369-2380.
133. Hoeffer C.A., Klann E. mTOR signaling: at the crossroads of plasticity, memory and disease. Trends in Neurosciences 2010, 33:67-75.
134. Banko J.L., Poulin F., Hou L., DeMaria C.T., Sonenberg N., Klann E. The translation repressor 4E-BP2 is critical for eIF4F complex formation, synaptic plasticity, and memory in the hippocampus. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2005, 25:9581-9590.
135. Banko J.L., Merhav M., Stern E., Sonenberg N., Rosenblum K., Klann E. Behavioral alterations in mice lacking the translation repressor 4E-BP2. Neurobiology of Learning and Memory 2007, 87:248-256.
136. Neasta J., Ben Hamida S., Yowell Q., Carnicella S., Ron D. Role for mammalian target of rapamycin complex 1 signaling in neuroadaptations underlying alcohol-related disorders. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:20093-20098.
137. Li N., Lee B., Liu R.J., Banasr M., Dwyer J.M., Iwata M., Li X.Y., Aghajanian G., Duman R.S. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010, 329:959-964.
138. Ehninger D., Silva A.J. Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders. Trends in Molecular Medicine 2011, 17:78-87.
139. Pitkanen A. Therapeutic approaches to epileptogenesis - hope on the horizon. Epilepsia 2010, 51(Suppl. 3):2-17.
140. Ljungberg M.C., Sunnen C.N., Lugo J.N., Anderson A.E., D'Arcangelo G. Rapamycin suppresses seizures and neuronal hypertrophy in a mouse model of cortical dysplasia. Disease Models & Mechanisms 2009, 2:389-398.
141. Uhlmann E.J., Wong M., Baldwin R.L., Bajenaru M.L., Onda H., Kwiatkowski D.J., Yamada K., Gutmann D.H. Astrocyte-specific TSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures. Annals of Neurology 2002, 52:285-296.
142. Krab L.C., Goorden S.M., Elgersma Y. Oncogenes on my mind: ERK and MTOR signaling in cognitive diseases. Trends in Genetics: TIG 2008, 24:498-510.
143. Ehninger D., Han S., Shilyansky C., Zhou Y., Li W., Kwiatkowski D.J., Ramesh V., Silva A.J. Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nature Medicine 2008, 14:843-848.
144. Park K.K., Liu K., Hu Y., Smith P.D., Wang C., Cai B., Xu B., Connolly L., Kramvis I., Sahin M., et al. Promoting axon regeneration in the adult CNS by modulation of the PTEN/mTOR pathway. Science 2008, 322:963-966.
145. Garelick M.G., Kennedy B.K. TOR on the brain. Experimental Gerontology 2011, 46:155-163.
146. Spilman P., Podlutskaya N., Hart M.J., Debnath J., Gorostiza O., Bredesen D., Richardson A., Strong R., Galvan V. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. PLoS ONE 2010, 5:e9979.
147. Ravikumar B., Vacher C., Berger Z., Davies J.E., Luo S., Oroz L.G., Scaravilli F., Easton D.F., Duden R., O'Kane C.J., et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nature Genetics 2004, 36:585-595.
148. Malagelada C., Ryu E.J., Biswas S.C., Jackson-Lewis V., Greene L.A. RTP801 is elevated in Parkinson brain substantia nigral neurons and mediates death in cellular models of Parkinson's disease by a mechanism involving mammalian target of rapamycin inactivation. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2006, 26:9996-10005.
149. Malagelada C., Jin Z.H., Jackson-Lewis V., Przedborski S., Greene L.A. Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2010, 30:1166-1175.
150. Cao K., Graziotto J.J., Blair C.D., Mazzulli J.R., Erdos M.R., Krainc D., Collins F.S. Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in Hutchinson-Gilford progeria syndrome cells. Science Translational Medicine 2011, 3:89ra58.
151. Weichhart T., Saemann M.D. The multiple facets of mTOR in immunity. Trends in Immunology 2009, 30:218-226.
152. Saemann M.D., Haidinger M., Hecking M., Horl W.H., Weichhart T. The multifunctional role of mTOR in innate immunity: implications for transplant immunity. American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2009, 9:2655-2661.
153. Gomez-Cambronero J., Horn J., Paul C.C., Baumann M.A. Granulocyte-macrophage colony-stimulating factor is a chemoattractant cytokine for human neutrophils: involvement of the ribosomal p70 S6 kinase signaling pathway. Journal of Immunology 2003, 171:6846-6855.
154. Kim M.S., Kuehn H.S., Metcalfe D.D., Gilfillan A.M. Activation and function of the mTORC1 pathway in mast cells. Journal of Immunology 2008, 180:4586-4595.
155. Cao W., Manicassamy S., Tang H., Kasturi S.P., Pirani A., Murthy N., Pulendran B. Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K pathway. Nature Immunology 2008, 9:1157-1164.
156. Weichhart T., Costantino G., Poglitsch M., Rosner M., Zeyda M., Stuhlmeier K.M., Kolbe T., Stulnig T.M., Horl W.H., Hengstschlager M., et al. The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 2008, 29:565-577.
157. Powell J.D., Delgoffe G.M. The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism. Immunity 2010, 33:301-311.
158. Delgoffe G.M., Kole T.P., Zheng Y., Zarek P.E., Matthews K.L., Xiao B., Worley P.F., Kozma S.C., Powell J.D. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 2009, 30:832-844.
159. Allen A., Zheng Y., Gardner L., Safford M., Horton M.R., Powell J.D. The novel cyclophilin binding compound, sanglifehrin A, disassociates G1 cell cycle arrest from tolerance induction. Journal of Immunology 2004, 172:4797-4803.
160. Zheng Y., Collins S.L., Lutz M.A., Allen A.N., Kole T.P., Zarek P.E., Powell J.D. A role for mammalian target of rapamycin in regulating T cell activation versus anergy. Journal of Immunology 2007, 178:2163-2170.
161. Pignataro G., Capone D., Polichetti G., Vinciguerra A., Gentile A., Di Renzo G., Annunziato L. Neuroprotective, immunosuppressant and antineoplastic properties of mTOR inhibitors: current and emerging therapeutic options. Current Opinion in Pharmacology 2011, 11:378-394.
162. Fernandez D., Perl A. mTOR signaling: a central pathway to pathogenesis in systemic lupus erythematosus?. Discovery Medicine 2010, 9:173-178.
163. Fernandez D., Bonilla E., Mirza N., Niland B., Perl A. Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis and Rheumatism 2006, 54:2983-2988.
164. Giordano A., Romano A. Inhibition of human in-stent restenosis: a molecular view. Current Opinion in Pharmacology 2011, 11:372-377.
165. Morice M.C., Serruys P.W., Sousa J.E., Fajadet J., Ban Hayashi E., Perin M., Colombo A., Schuler G., Barragan P., Guagliumi G., et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. The New England Journal of Medicine 2002, 346:1773-1780.
166. Aoyagi T., Matsui T. Phosphoinositide-3 kinase signaling in cardiac hypertrophy and heart failure. Current Pharmaceutical Design 2011, [Epub ahead of print], PMID: 21631421.
167. Zhang D., Contu R., Latronico M.V., Zhang J., Rizzi R., Catalucci D., Miyamoto S., Huang K., Ceci M., Gu Y., et al. MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice. The Journal of Clinical Investigation 2010, 120:2805-2816.
168. Shende P., Plaisance I., Morandi C., Pellieux C., Berthonneche C., Zorzato F., Krishnan J., Lerch R., Hall M.N., Ruegg M.A., et al. Cardiac raptor ablation impairs adaptive hypertrophy, alters metabolic gene expression, and causes heart failure in mice. Circulation 2011, 123:1073-1082.